Although initially formally described in the 19th century, the diversity of presentation and clinical subsets of Kaposi sarcoma have expanded considerably since then. Now recognised as a virally driven process caused by human herpesvirus 8, co‐infection with HIV or EBV, as well as immunosuppression, are considered important predisposing factors. This has resulted in marked increases in incidence across multiple populations. Accordingly, these clinical subsets require different therapeutic approaches even as molecular profiling highlight largely overlapping features.